Assesment of Lactulose vs Lactobacillus Acidophilus Effect in CKD Patients
Study Details
Study Description
Brief Summary
Assessment for usage of laxatives and probiotics ,and its role in improving uremic parameters of CKD as GFR, UREA ,CREATININE, CLINICAL and UREMIC assessment (lower limb edema ,UOP,base of chest ,vomiting ,dyspnea,blood pressure measurement)
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
Detailed Description
with advanced CKD stages ,also have been linked to the high prevalence of constipation in CKD,Lactulose is a synthetic disaccharide.Lactulose is poorly absorbed from the gastrointestinal tract remains virtually unchanged and is then fermented by gut microbiota that increase osmotic effects and intraluminal gas formation . lactulose reduces the nitrogen products and urea, creatinine, uric acid, and b2- microglobulin levels. Lactulose also suppress tubulointerstitial fibrosis in a rat model of a kidney disease study . Lactulose modifies the gut microbiota, increasing the abundance of Bifidobacteria and Lactobacilli after 8 weeks of 30 ml lactulose syrup thrice daily, and ameliorates CKD progression by suppressing uremic toxin production .probiotics include vast array of products with living organisms whose purpose is to improve intestinal microbial balance and produce beneficial effect on ones health .probiotics is an alternative therapy for patients with CKD
Study Design
Outcome Measures
Primary Outcome Measures
- Assessment for usage of laxatives and probiotics ,and its role in improving uremic parameters in CKD patients and compare between both. [1 year]
Assessment for usage of laxatives and probiotics ,and its role in improving uremic parameters in CKD patients and compare between both.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
CKD stages 3,4,5 with non-dialysis receiving a diagnosis of constipation
-
DM nephropathy
Exclusion Criteria:
-
IBS (ulcerative colitis -crohns)
-
HCV ,HBV ,
-
autoimmune patients,
-
malignancy pt
-
cirrhotic patients
-
haemodialysis patients
-
cardiovascular patients
-
abdominal surgery,
-
gut obstruction,
-
pregnancy,
-
patients with ESRD on dialysis,
-
history of lactulose allergy.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Assiut University
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
- Tayebi Khosroshahi H, Habibzadeh A, Khoshbaten M, Rahbari B, Chaichi P, Badiee AH. Lactulose for reduction of nitrogen products in patients with chronic kidney disease. Iran J Kidney Dis. 2014 Sep;8(5):377-81.
- Tayebi-Khosroshahi H, Habibzadeh A, Niknafs B, Ghotaslou R, Yeganeh Sefidan F, Ghojazadeh M, Moghaddaszadeh M, Parkhide S. The effect of lactulose supplementation on fecal microflora of patients with chronic kidney disease; a randomized clinical trial. J Renal Inj Prev. 2016 Jul 29;5(3):162-7. doi: 10.15171/jrip.2016.34. eCollection 2016.
- lactulose in CKD patients .